{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T07:15:51Z","timestamp":1778397351632,"version":"3.51.4"},"reference-count":168,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T00:00:00Z","timestamp":1564704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002997","name":"Nierstichting","doi-asserted-by":"publisher","award":["15OKG16"],"award-info":[{"award-number":["15OKG16"]}],"id":[{"id":"10.13039\/501100002997","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00467-019-04304-9","type":"journal-article","created":{"date-parts":[[2019,8,2]],"date-time":"2019-08-02T13:05:49Z","timestamp":1564751149000},"page":"1153-1172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetics in children with chronic kidney disease"],"prefix":"10.1007","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2418-8928","authenticated-orcid":false,"given":"Anne M.","family":"Schijvens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia N.","family":"de Wildt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiel F.","family":"Schreuder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,2]]},"reference":[{"key":"4304_CR1","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1038\/ki.2013.399","volume":"85","author":"CK Yeung","year":"2014","unstructured":"Yeung CK, Shen DD, Thummel KE, Himmelfarb J (2014) Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport. Kidney Int 85:522\u2013528. https:\/\/doi.org\/10.1038\/ki.2013.399","journal-title":"Kidney Int"},{"key":"4304_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00467-011-1939-1","volume":"27","author":"J Harambat","year":"2012","unstructured":"Harambat J, van Stralen KJ, Kim JJ, Tizard EJ (2012) Epidemiology of chronic kidney disease in children. Pediatr Nephrol 27:363\u2013373. https:\/\/doi.org\/10.1007\/s00467-011-1939-1","journal-title":"Pediatr Nephrol"},{"key":"4304_CR3","doi-asserted-by":"publisher","first-page":"e382","DOI":"10.1542\/peds.111.4.e382","volume":"111","author":"G Ardissino","year":"2003","unstructured":"Ardissino G, Dacco V, Testa S, Bonaudo R, Claris-Appiani A, Taioli E, Marra G, Edefonti A, Sereni F, ItalKid Project (2003) Epidemiology of chronic renal failure in children: data from the ItalKid project. Pediatrics 111:e382\u2013e387","journal-title":"Pediatrics"},{"key":"4304_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/sdi.12374","volume":"28","author":"TD Nolin","year":"2015","unstructured":"Nolin TD (2015) A synopsis of clinical pharmacokinetic alterations in advanced CKD. Semin Dial 28:325\u2013329. https:\/\/doi.org\/10.1111\/sdi.12374","journal-title":"Semin Dial"},{"key":"4304_CR5","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2215\/CJN.00340118","volume":"13","author":"TN Lea-Henry","year":"2018","unstructured":"Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM (2018) Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol 13:1085\u20131095. https:\/\/doi.org\/10.2215\/CJN.00340118","journal-title":"Clin J Am Soc Nephrol"},{"key":"4304_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2165\/00003088-199732010-00002","volume":"32","author":"YW Lam","year":"1997","unstructured":"Lam YW, Banerji S, Hatfield C, Talbert RL (1997) Principles of drug administration in renal insufficiency. Clin Pharmacokinet 32:30\u201357. https:\/\/doi.org\/10.2165\/00003088-199732010-00002","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR7","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1001\/archinte.159.21.2553","volume":"159","author":"DW Bates","year":"1999","unstructured":"Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, Petersen LA, Small SD, Sweitzer BJ, Vander Vliet M, Leape LL (1999) Patient risk factors for adverse drug events in hospitalized patients. ADE Prevention Study Group. Arch Intern Med 159:2553\u20132560","journal-title":"Arch Intern Med"},{"key":"4304_CR8","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1053\/j.ackd.2010.06.004","volume":"17","author":"KE Cardone","year":"2010","unstructured":"Cardone KE, Bacchus S, Assimon MM, Pai AB, Manley HJ (2010) Medication-related problems in CKD. Adv Chronic Kidney Dis 17:404\u2013412. https:\/\/doi.org\/10.1053\/j.ackd.2010.06.004","journal-title":"Adv Chronic Kidney Dis"},{"key":"4304_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00467-012-2149-1","volume":"28","author":"N Ibrahim","year":"2013","unstructured":"Ibrahim N, Wong IC, Patey S, Tomlin S, Sinha MD, Jani Y (2013) Drug-related problem in children with chronic kidney disease. Pediatr Nephrol 28:25\u201331. https:\/\/doi.org\/10.1007\/s00467-012-2149-1","journal-title":"Pediatr Nephrol"},{"key":"4304_CR10","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/ki.2011.322","volume":"80","author":"GR Matzke","year":"2011","unstructured":"Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, Golper T, Grabe DW, Kasiske B, Keller F, Kielstein JT, Mehta R, Mueller BA, Pasko DA, Schaefer F, Sica DA, Inker LA, Umans JG, Murray P (2011) Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 80:1122\u20131137. https:\/\/doi.org\/10.1038\/ki.2011.322","journal-title":"Kidney Int"},{"issue":"Suppl 10","key":"4304_CR11","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1002\/jcph.1284","volume":"58","author":"J van den Anker","year":"2018","unstructured":"van den Anker J, Reed MD, Allegaert K, Kearns GL (2018) Developmental changes in pharmacokinetics and pharmacodynamics. J Clin Pharmacol 58(Suppl 10):S10\u2013S25. https:\/\/doi.org\/10.1002\/jcph.1284","journal-title":"J Clin Pharmacol"},{"key":"4304_CR12","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE (2003) Developmental pharmacology--drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157\u20131167. https:\/\/doi.org\/10.1056\/NEJMra035092","journal-title":"N Engl J Med"},{"key":"4304_CR13","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s40262-015-0298-7","volume":"54","author":"F Rodieux","year":"2015","unstructured":"Rodieux F, Wilbaux M, van den Anker JN, Pfister M (2015) Effect of kidney function on drug kinetics and dosing in neonates, infants, and children. Clin Pharmacokinet 54:1183\u20131204. https:\/\/doi.org\/10.1007\/s40262-015-0298-7","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1542\/peds.108.5.1089","volume":"108","author":"GW t\u2019Jong","year":"2001","unstructured":"t\u2019Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN (2001) A survey of the use of off-label and unlicensed drugs in a Dutch children\u2019s hospital. Pediatrics 108:1089\u20131093","journal-title":"Pediatrics"},{"key":"4304_CR15","unstructured":"Birkett DJ (1998) Pharmacokinetics made easy. Sydney, McGraw-Hill Education"},{"key":"4304_CR16","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1124\/dmd.118.084418","volume":"47","author":"A Neal-Kluever","year":"2019","unstructured":"Neal-Kluever A, Fisher J, Grylack L, Kakiuchi-Kiyota S, Halpern W (2019) Physiology of the neonatal gastrointestinal system relevant to the disposition of orally administered medications. Drug Metab Dispos 47:296\u2013313. https:\/\/doi.org\/10.1124\/dmd.118.084418","journal-title":"Drug Metab Dispos"},{"key":"4304_CR17","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1517\/17425255.2012.698261","volume":"8","author":"MG Mooij","year":"2012","unstructured":"Mooij MG, de Koning BA, Huijsman ML, de Wildt SN (2012) Ontogeny of oral drug absorption processes in children. Expert Opin Drug Metab Toxicol 8:1293\u20131303. https:\/\/doi.org\/10.1517\/17425255.2012.698261","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4304_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/bdd.1937","volume":"36","author":"JJ Bonner","year":"2015","unstructured":"Bonner JJ, Vajjah P, Abduljalil K, Jamei M, Rostami-Hodjegan A, Tucker GT, Johnson TN (2015) Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults. Biopharm Drug Dispos 36:245\u2013257. https:\/\/doi.org\/10.1002\/bdd.1937","journal-title":"Biopharm Drug Dispos"},{"key":"4304_CR19","first-page":"577","volume":"44","author":"C Billeaud","year":"1990","unstructured":"Billeaud C, Guillet J, Sandler B (1990) Gastric emptying in infants with or without gastro-oesophageal reflux according to the type of milk. Eur J Clin Nutr 44:577\u2013583","journal-title":"Eur J Clin Nutr"},{"key":"4304_CR20","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1097\/00000542-200206000-00012","volume":"96","author":"BJ Anderson","year":"2002","unstructured":"Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 96:1336\u20131345","journal-title":"Anesthesiology"},{"key":"4304_CR21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/00005176-200406001-00133","volume":"39","author":"S Bode","year":"2004","unstructured":"Bode S, Dreyer M, Greisen G (2004) Gastric emptying and small intestinal transit time in preterm infants: a scintigraphic method. J Pediatr Gastroenterol Nutr 39:378\u2013382","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"4304_CR22","first-page":"27","volume":"7","author":"A Hubalewska","year":"2004","unstructured":"Hubalewska A, Stompor T, Placzkiewicz E, Staszczak A, Huszno B, Sulowicz W, Szybinski Z (2004) Evaluation of gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis using 99mTc-solid meal. Nucl Med Rev Cent East Eur 7:27\u201330","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"4304_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/00004836-198712000-00008","volume":"9","author":"EE Soffer","year":"1987","unstructured":"Soffer EE, Geva B, Helman C, Avni Y, Bar-Meir S (1987) Gastric emptying in chronic renal failure patients on hemodialysis. J Clin Gastroenterol 9:651\u2013653","journal-title":"J Clin Gastroenterol"},{"key":"4304_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/00365520410004505","volume":"39","author":"H Strid","year":"2004","unstructured":"Strid H, Simren M, Stotzer PO, Abrahamsson H, Bjornsson ES (2004) Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol 39:516\u2013520. https:\/\/doi.org\/10.1080\/00365520410004505","journal-title":"Scand J Gastroenterol"},{"key":"4304_CR25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/jgh.13458","volume":"32","author":"CJ Grant","year":"2017","unstructured":"Grant CJ, Harrison LE, Hoad CL, Marciani L, Gowland PA, McIntyre CW (2017) Patients with chronic kidney disease have abnormal upper gastro-intestinal tract digestive function: a study of uremic enteropathy. J Gastroenterol Hepatol 32:372\u2013377. https:\/\/doi.org\/10.1111\/jgh.13458","journal-title":"J Gastroenterol Hepatol"},{"key":"4304_CR26","doi-asserted-by":"publisher","first-page":"210","DOI":"10.2165\/00003088-199018030-00003","volume":"18","author":"R Gugler","year":"1990","unstructured":"Gugler R, Allgayer H (1990) Effects of antacids on the clinical pharmacokinetics of drugs. An update. Clin Pharmacokinet 18:210\u2013219","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/BF03226367","volume":"20","author":"SE Bellibas","year":"1995","unstructured":"Bellibas SE, Tuglular I, Kayali A (1995) The effect of delayed gastric emptying and absorption on pharmacokinetic parameters of lithium. Eur J Drug Metab Pharmacokinet 20:129\u2013133. https:\/\/doi.org\/10.1007\/BF03226367","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"4304_CR28","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1136\/adc.67.11.1343","volume":"67","author":"AM Ravelli","year":"1992","unstructured":"Ravelli AM, Ledermann SE, Bisset WM, Trompeter RS, Barratt TM, Milla PJ (1992) Foregut motor function in chronic renal failure. Arch Dis Child 67:1343\u20131347. https:\/\/doi.org\/10.1136\/adc.67.11.1343","journal-title":"Arch Dis Child"},{"key":"4304_CR29","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/BF00850220","volume":"3","author":"EJ Ruley","year":"1989","unstructured":"Ruley EJ, Bock GH, Kerzner B, Abbott AW, Majd M, Chatoor I (1989) Feeding disorders and gastroesophageal reflux in infants with chronic renal failure. Pediatr Nephrol 3:424\u2013429","journal-title":"Pediatr Nephrol"},{"key":"4304_CR30","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1542\/peds.37.6.1005","volume":"37","author":"GB Avery","year":"1966","unstructured":"Avery GB, Randolph JG, Weaver T (1966) Gastric acidity in the first day of life. Pediatrics 37:1005\u20131007","journal-title":"Pediatrics"},{"key":"4304_CR31","doi-asserted-by":"publisher","first-page":"F517","DOI":"10.1136\/fn.88.6.F517","volume":"88","author":"TI Omari","year":"2003","unstructured":"Omari TI, Davidson GP (2003) Multipoint measurement of intragastric pH in healthy preterm infants. Arch Dis Child Fetal Neonatal Ed 88:F517\u2013F520","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"4304_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2165\/00003088-199222030-00002","volume":"22","author":"WL St Peter","year":"1992","unstructured":"St Peter WL, Redic-Kill KA, Halstenson CE (1992) Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet 22:169\u2013210. https:\/\/doi.org\/10.2165\/00003088-199222030-00002","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR33","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1681\/ASN.2013080905","volume":"25","author":"A Ramezani","year":"2014","unstructured":"Ramezani A, Raj DS (2014) The gut microbiome, kidney disease, and targeted interventions. J Am Soc Nephrol 25:657\u2013670. https:\/\/doi.org\/10.1681\/ASN.2013080905","journal-title":"J Am Soc Nephrol"},{"key":"4304_CR34","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.mcna.2004.11.007","volume":"89","author":"S Gabardi","year":"2005","unstructured":"Gabardi S, Abramson S (2005) Drug dosing in chronic kidney disease. Med Clin North Am 89:649\u2013687. https:\/\/doi.org\/10.1016\/j.mcna.2004.11.007","journal-title":"Med Clin North Am"},{"key":"4304_CR35","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/cpt1978236644","volume":"23","author":"WJ Tilstone","year":"1978","unstructured":"Tilstone WJ, Fine A (1978) Furosemide kinetics in renal failure. Clin Pharmacol Ther 23:644\u2013650","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR36","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1001\/jama.1986.03370110090027","volume":"255","author":"MA O'Neil-Cutting","year":"1986","unstructured":"O'Neil-Cutting MA, Crosby WH (1986) The effect of antacids on the absorption of simultaneously ingested iron. JAMA 255:1468\u20131470","journal-title":"JAMA"},{"key":"4304_CR37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1007\/BF00868736","volume":"9","author":"AM Ravelli","year":"1995","unstructured":"Ravelli AM (1995) Gastrointestinal function in chronic renal failure. Pediatr Nephrol 9:756\u2013762","journal-title":"Pediatr Nephrol"},{"key":"4304_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3389\/fped.2018.00205","volume":"6","author":"DM Silverstein","year":"2018","unstructured":"Silverstein DM (2018) Growth and nutrition in pediatric chronic kidney disease. Front Pediatr 6:205. https:\/\/doi.org\/10.3389\/fped.2018.00205","journal-title":"Front Pediatr"},{"key":"4304_CR39","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2215\/CJN.01580407","volume":"2","author":"PP How","year":"2007","unstructured":"How PP, Fischer JH, Arruda JA, Lau AH (2007) Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin J Am Soc Nephrol 2:1235\u20131240. https:\/\/doi.org\/10.2215\/CJN.01580407","journal-title":"Clin J Am Soc Nephrol"},{"key":"4304_CR40","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1053\/j.ajkd.2003.08.027","volume":"42","author":"MB Kays","year":"2003","unstructured":"Kays MB, Overholser BR, Mueller BA, Moe SM, Sowinski KM (2003) Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am J Kidney Dis 42:1253\u20131259","journal-title":"Am J Kidney Dis"},{"key":"4304_CR41","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/0091270011413588","volume":"52","author":"J Naud","year":"2012","unstructured":"Naud J, Nolin TD, Leblond FA, Pichette V (2012) Current understanding of drug disposition in kidney disease. J Clin Pharmacol 52:10S\u201322S. https:\/\/doi.org\/10.1177\/0091270011413588","journal-title":"J Clin Pharmacol"},{"key":"4304_CR42","first-page":"1552","volume":"283","author":"MF Paine","year":"1997","unstructured":"Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, Perkins JD, Thummel KE (1997) Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. J Pharmacol Exp Ther 283:1552\u20131562","journal-title":"J Pharmacol Exp Ther"},{"key":"4304_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0009-9236(96)90162-9","volume":"60","author":"MF Paine","year":"1996","unstructured":"Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14\u201324. https:\/\/doi.org\/10.1016\/S0009-9236(96)90162-9","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR44","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/0140-6736(91)92302-I","volume":"338","author":"JC Kolars","year":"1991","unstructured":"Kolars JC, Awni WM, Merion RM, Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet 338:1488\u20131490","journal-title":"Lancet"},{"key":"4304_CR45","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","volume":"48","author":"T Vanhove","year":"2016","unstructured":"Vanhove T, Annaert P, Kuypers DR (2016) Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev 48:88\u2013112. https:\/\/doi.org\/10.3109\/03602532.2016.1151037","journal-title":"Drug Metab Rev"},{"key":"4304_CR46","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.clpt.2005.05.011","volume":"78","author":"RH Ho","year":"2005","unstructured":"Ho RH, Kim RB (2005) Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther 78:260\u2013277. https:\/\/doi.org\/10.1016\/j.clpt.2005.05.011","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.05.010","volume":"109","author":"H Sun","year":"2006","unstructured":"Sun H, Frassetto L, Benet LZ (2006) Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109:1\u201311. https:\/\/doi.org\/10.1016\/j.pharmthera.2005.05.010","journal-title":"Pharmacol Ther"},{"key":"4304_CR48","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1002\/hep.23233","volume":"50","author":"MK DeGorter","year":"2009","unstructured":"DeGorter MK, Kim RB (2009) Hepatic drug transporters, old and new: pharmacogenomics, drug response, and clinical relevance. Hepatology 50:1014\u20131016. https:\/\/doi.org\/10.1002\/hep.23233","journal-title":"Hepatology"},{"key":"4304_CR49","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1124\/pr.113.007518","volume":"65","author":"J Konig","year":"2013","unstructured":"Konig J, Muller F, Fromm MF (2013) Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev 65:944\u2013966. https:\/\/doi.org\/10.1124\/pr.113.007518","journal-title":"Pharmacol Rev"},{"key":"4304_CR50","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1006\/scbi.1997.0068","volume":"8","author":"AH Schinkel","year":"1997","unstructured":"Schinkel AH (1997) The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol 8:161\u2013170. https:\/\/doi.org\/10.1006\/scbi.1997.0068","journal-title":"Semin Cancer Biol"},{"key":"4304_CR51","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.ajkd.2003.07.019","volume":"42","author":"TD Nolin","year":"2003","unstructured":"Nolin TD, Frye RF, Matzke GR (2003) Hepatic drug metabolism and transport in patients with kidney disease. Am J Kidney Dis 42:906\u2013925","journal-title":"Am J Kidney Dis"},{"key":"4304_CR52","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s40262-015-0328-5","volume":"55","author":"MG Mooij","year":"2016","unstructured":"Mooij MG, Nies AT, Knibbe CA, Schaeffeler E, Tibboel D, Schwab M, de Wildt SN (2016) Development of human membrane transporters: drug disposition and pharmacogenetics. Clin Pharmacokinet 55:507\u2013524. https:\/\/doi.org\/10.1007\/s40262-015-0328-5","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR53","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1124\/dmd.105.005611","volume":"33","author":"M Fakhoury","year":"2005","unstructured":"Fakhoury M, Litalien C, Medard Y, Cave H, Ezzahir N, Peuchmaur M, Jacqz-Aigrain E (2005) Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab Dispos 33:1603\u20131607. https:\/\/doi.org\/10.1124\/dmd.105.005611","journal-title":"Drug Metab Dispos"},{"key":"4304_CR54","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1124\/dmd.114.056929","volume":"42","author":"MG Mooij","year":"2014","unstructured":"Mooij MG, Schwarz UI, de Koning BA, Leeder JS, Gaedigk R, Samsom JN, Spaans E, van Goudoever JB, Tibboel D, Kim RB, de Wildt SN (2014) Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. Drug Metab Dispos 42:1268\u20131274. https:\/\/doi.org\/10.1124\/dmd.114.056929","journal-title":"Drug Metab Dispos"},{"key":"4304_CR55","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1046\/j.1365-2125.2001.01370.x","volume":"51","author":"TN Johnson","year":"2001","unstructured":"Johnson TN, Tanner MS, Taylor CJ, Tucker GT (2001) Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis. Br J Clin Pharmacol 51:451\u2013460","journal-title":"Br J Clin Pharmacol"},{"key":"4304_CR56","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s11095-018-2458-6","volume":"35","author":"JM Brussee","year":"2018","unstructured":"Brussee JM, Yu H, Krekels EHJ, Palic S, Brill MJE, Barrett JS, Rostami-Hodjegan A, de Wildt SN, Knibbe CAJ (2018) Characterization of intestinal and hepatic CYP3A-mediated metabolism of midazolam in children using a physiological population pharmacokinetic modelling approach. Pharm Res 35:182. https:\/\/doi.org\/10.1007\/s11095-018-2458-6","journal-title":"Pharm Res"},{"key":"4304_CR57","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/psp4.12295","volume":"7","author":"JM Brussee","year":"2018","unstructured":"Brussee JM, Yu H, Krekels EHJ, de Roos B, Brill MJE, van den Anker JN, Rostami-Hodjegan A, de Wildt SN, Knibbe CAJ (2018) First-pass CYP3A-mediated metabolism of midazolam in the gut wall and liver in preterm neonates. CPT Pharmacometrics Syst Pharmacol 7:374\u2013383. https:\/\/doi.org\/10.1002\/psp4.12295","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4304_CR58","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1124\/jpet.106.112631","volume":"320","author":"J Naud","year":"2007","unstructured":"Naud J, Michaud J, Boisvert C, Desbiens K, Leblond FA, Mitchell A, Jones C, Bonnardeaux A, Pichette V (2007) Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther 320:978\u2013985. https:\/\/doi.org\/10.1124\/jpet.106.112631","journal-title":"J Pharmacol Exp Ther"},{"key":"4304_CR59","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1093\/ndt\/16.8.1607","volume":"16","author":"C Veau","year":"2001","unstructured":"Veau C, Leroy C, Banide H, Auchere D, Tardivel S, Farinotti R, Lacour B (2001) Effect of chronic renal failure on the expression and function of rat intestinal P-glycoprotein in drug excretion. Nephrol Dial Transplant 16:1607\u20131614","journal-title":"Nephrol Dial Transplant"},{"key":"4304_CR60","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1097\/01.ASN.0000017575.50319.77","volume":"13","author":"FA Leblond","year":"2002","unstructured":"Leblond FA, Petrucci M, Dube P, Bernier G, Bonnardeaux A, Pichette V (2002) Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 13:1579\u20131585","journal-title":"J Am Soc Nephrol"},{"key":"4304_CR61","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1053\/j.ackd.2010.05.009","volume":"17","author":"JD Momper","year":"2010","unstructured":"Momper JD, Venkataramanan R, Nolin TD (2010) Nonrenal drug clearance in CKD: searching for the path less traveled. Adv Chronic Kidney Dis 17:384\u2013391. https:\/\/doi.org\/10.1053\/j.ackd.2010.05.009","journal-title":"Adv Chronic Kidney Dis"},{"key":"4304_CR62","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2165\/00003088-200140030-00002","volume":"40","author":"Y Zhang","year":"2001","unstructured":"Zhang Y, Benet LZ (2001) The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159\u2013168. https:\/\/doi.org\/10.2165\/00003088-200140030-00002","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR63","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1681\/ASN.2009010082","volume":"20","author":"TD Nolin","year":"2009","unstructured":"Nolin TD, Frye RF, Le P, Sadr H, Naud J, Leblond FA, Pichette V, Himmelfarb J (2009) ESKD impairs nonrenal clearance of fexofenadine but not midazolam. J Am Soc Nephrol 20:2269\u20132276. https:\/\/doi.org\/10.1681\/ASN.2009010082","journal-title":"J Am Soc Nephrol"},{"key":"4304_CR64","first-page":"1108","volume":"27","author":"M Yasuhara","year":"1995","unstructured":"Yasuhara M, Hashida T, Toraguchi M, Hashimoto Y, Kimura M, Inui K, Hori R, Inomata Y, Tanaka K, Yamaoka Y (1995) Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. Transplant Proc 27:1108\u20131110","journal-title":"Transplant Proc"},{"key":"4304_CR65","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1034\/j.1399-3046.2001.t01-1-00041.x","volume":"5","author":"N Sano","year":"2001","unstructured":"Sano N, Nio M, Shimaoka S, Ishii T, Amae S, Wada M, Ohi R (2001) High trough levels of oral FK506 induced by loss of small intestine. Pediatr Transplant 5:434\u2013438","journal-title":"Pediatr Transplant"},{"key":"4304_CR66","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/j.transproceed.2004.06.026","volume":"36","author":"T Asano","year":"2004","unstructured":"Asano T, Nishimoto K, Hayakawa M (2004) Increased tacrolimus trough levels in association with severe diarrhea, a case report. Transplant Proc 36:2096\u20132097. https:\/\/doi.org\/10.1016\/j.transproceed.2004.06.026","journal-title":"Transplant Proc"},{"key":"4304_CR67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1034\/j.1399-3046.2000.00086.x","volume":"4","author":"SK Eades","year":"2000","unstructured":"Eades SK, Boineau FG, Christensen ML (2000) Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea. Pediatr Transplant 4:63\u201366","journal-title":"Pediatr Transplant"},{"key":"4304_CR68","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2215\/CJN.05150418","volume":"13","author":"DM Roberts","year":"2018","unstructured":"Roberts DM, Sevastos J, Carland JE, Stocker SL, Lea-Henry TN (2018) Clinical pharmacokinetics in kidney disease: application to rational design of dosing regimens. Clin J Am Soc Nephrol 13:1254\u20131263. https:\/\/doi.org\/10.2215\/CJN.05150418","journal-title":"Clin J Am Soc Nephrol"},{"key":"4304_CR69","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/MNH.0b013e328358c8d5","volume":"21","author":"ND Vaziri","year":"2012","unstructured":"Vaziri ND (2012) CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 21:587\u2013592. https:\/\/doi.org\/10.1097\/MNH.0b013e328358c8d5","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4304_CR70","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/BF00565004","volume":"3","author":"M Ehrnebo","year":"1971","unstructured":"Ehrnebo M, Agurell S, Jalling B, Boreus LO (1971) Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol 3:189\u2013193","journal-title":"Eur J Clin Pharmacol"},{"key":"4304_CR71","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1749-6632.1973.tb20473.x","volume":"226","author":"J Krasner","year":"1973","unstructured":"Krasner J, Giacoia GP, Yaffe SJ (1973) Drug-protein binding in the newborn infant. Ann N Y Acad Sci 226:101\u2013114. https:\/\/doi.org\/10.1111\/j.1749-6632.1973.tb20473.x","journal-title":"Ann N Y Acad Sci"},{"key":"4304_CR72","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s10096-018-3277-8","volume":"37","author":"A Smits","year":"2018","unstructured":"Smits A, Pauwels S, Oyaert M, Peersman N, Spriet I, Saegeman V, Allegaert K (2018) Factors impacting unbound vancomycin concentrations in neonates and young infants. Eur J Clin Microbiol Infect Dis 37:1503\u20131510. https:\/\/doi.org\/10.1007\/s10096-018-3277-8","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4304_CR73","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000166900","volume":"5","author":"DB Haughey","year":"1985","unstructured":"Haughey DB, Kraft CJ, Matzke GR, Keane WF, Halstenson CE (1985) Protein binding of disopyramide and elevated alpha-1-acid glycoprotein concentrations in serum obtained from dialysis patients and renal transplant recipients. Am J Nephrol 5:35\u201339","journal-title":"Am J Nephrol"},{"key":"4304_CR74","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1159\/000187492","volume":"65","author":"MP Vasson","year":"1993","unstructured":"Vasson MP, Baguet JC, Arveiller MR, Bargnoux PJ, Giroud JP, Raichvarg D (1993) Serum and urinary alpha-1 acid glycoprotein in chronic renal failure. Nephron 65:299\u2013303","journal-title":"Nephron"},{"key":"4304_CR75","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ki.1988.99","volume":"33","author":"R Vanholder","year":"1988","unstructured":"Vanholder R, Van Landschoot N, De Smet R, Schoots A, Ringoir S (1988) Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int 33:996\u20131004","journal-title":"Kidney Int"},{"issue":"Suppl 1","key":"4304_CR76","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2165\/00003088-198400091-00003","volume":"9","author":"MM Reidenberg","year":"1984","unstructured":"Reidenberg MM, Drayer DE (1984) Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 9(Suppl 1):18\u201326","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR77","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2165\/00002018-199716030-00005","volume":"16","author":"GR Matzke","year":"1997","unstructured":"Matzke GR, Frye RF (1997) Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity. Drug Saf 16:205\u2013231","journal-title":"Drug Saf"},{"key":"4304_CR78","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1023\/A:1011014629551","volume":"18","author":"T Sakai","year":"2001","unstructured":"Sakai T, Yamasaki K, Sako T, Kragh-Hansen U, Suenaga A, Otagiri M (2001) Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm Res 18:520\u2013524","journal-title":"Pharm Res"},{"key":"4304_CR79","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1517\/17425255.2014.931371","volume":"10","author":"TJ Velenosi","year":"2014","unstructured":"Velenosi TJ, Urquhart BL (2014) Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol 10:1131\u20131143. https:\/\/doi.org\/10.1517\/17425255.2014.931371","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"Suppl 1","key":"4304_CR80","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1007\/BF01428386","volume":"44","author":"R Vanholder","year":"1993","unstructured":"Vanholder R, De Smet R, Ringoir S (1993) Factors influencing drug protein binding in patients with end stage renal failure. Eur J Clin Pharmacol 44(Suppl 1):S17\u2013S21","journal-title":"Eur J Clin Pharmacol"},{"key":"4304_CR81","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1067\/mcp.2002.121829","volume":"71","author":"LZ Benet","year":"2002","unstructured":"Benet LZ, Hoener BA (2002) Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 71:115\u2013121. https:\/\/doi.org\/10.1067\/mcp.2002.121829","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR82","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/j.1552-4604.1986.tb02971.x","volume":"26","author":"GR Matzke","year":"1986","unstructured":"Matzke GR, Brundage RC, Sawchuk RJ (1986) Protein binding of phenytoin, p-hydroxy phenytoin, and p-hydroxy phenytoin glucuronide. J Clin Pharmacol 26:677\u2013679","journal-title":"J Clin Pharmacol"},{"key":"4304_CR83","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s00228-009-0678-8","volume":"65","author":"RK Verbeeck","year":"2009","unstructured":"Verbeeck RK, Musuamba FT (2009) Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol 65:757\u2013773. https:\/\/doi.org\/10.1007\/s00228-009-0678-8","journal-title":"Eur J Clin Pharmacol"},{"key":"4304_CR84","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/j.1552-4604.1974.tb01367.x","volume":"14","author":"WJ Jusko","year":"1974","unstructured":"Jusko WJ, Szefler SJ, Goldfarb AL (1974) Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol 14:525\u2013535","journal-title":"J Clin Pharmacol"},{"key":"4304_CR85","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/BF01061728","volume":"5","author":"LB Sheiner","year":"1977","unstructured":"Sheiner LB, Rosenberg B, Marathe VV (1977) Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 5:445\u2013479","journal-title":"J Pharmacokinet Biopharm"},{"key":"4304_CR86","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1111\/j.1365-2125.1976.tb00356.x","volume":"3","author":"JK Aronson","year":"1976","unstructured":"Aronson JK, Grahame-Smith DG (1976) Altered distribution of digoxin in renal failure--a cause of digoxin toxicity? Br J Clin Pharmacol 3:1045\u20131051","journal-title":"Br J Clin Pharmacol"},{"key":"4304_CR87","series-title":"International Boehringer Mannheim Symposia","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-66904-0","volume-title":"Cardiac Glycosides","year":"1978","unstructured":"Bodem G, Dengler HJ (1978) Cardiac glycosides. Berlin Heidelberg, Springer-Verlag, pp 265\u2013272. https:\/\/doi.org\/10.1007\/978-3-642-66904-0"},{"key":"4304_CR88","unstructured":"Rowland M, Tozer TN (2010) Clinical pharmacokinetics and pharmacodynamics: concepts and applications (4th ed). Philadelphia, PA, Lippincott Williams and Wilkins"},{"key":"4304_CR89","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1021\/tx700079z","volume":"21","author":"FP Guengerich","year":"2008","unstructured":"Guengerich FP (2008) Cytochrome p450 and chemical toxicology. Chem Res Toxicol 21:70\u201383. https:\/\/doi.org\/10.1021\/tx700079z","journal-title":"Chem Res Toxicol"},{"key":"4304_CR90","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN (1999) Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 37:485\u2013505. https:\/\/doi.org\/10.2165\/00003088-199937060-00004","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR91","unstructured":"Flockhart DA (2007) Drug interactions: cytochrome P450 drug interaction table. Indiana University School of Medicine. https:\/\/drug-interactions.medicine.iu.edu . Accessed 3 Jan 2019"},{"key":"4304_CR92","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/cpt.337","volume":"100","author":"K Yoshida","year":"2016","unstructured":"Yoshida K, Sun B, Zhang L, Zhao P, Abernethy DR, Nolin TD, Rostami-Hodjegan A, Zineh I, Huang SM (2016) Systematic and quantitative assessment of the effect of chronic kidney disease on CYP2D6 and CYP3A4\/5. Clin Pharmacol Ther 100:75\u201387. https:\/\/doi.org\/10.1002\/cpt.337","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR93","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/clpt.2009.163","volume":"86","author":"AW Dreisbach","year":"2009","unstructured":"Dreisbach AW (2009) The influence of chronic renal failure on drug metabolism and transport. Clin Pharmacol Ther 86:553\u2013556. https:\/\/doi.org\/10.1038\/clpt.2009.163","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR94","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1124\/dmd.107.018747","volume":"36","author":"ET Morgan","year":"2008","unstructured":"Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, Richardson TA, Sharma R, Sinal CJ (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205\u2013216. https:\/\/doi.org\/10.1124\/dmd.107.018747","journal-title":"Drug Metab Dispos"},{"key":"4304_CR95","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1042\/CS20160191","volume":"131","author":"J Jansen","year":"2017","unstructured":"Jansen J, Jankowski J, Gajjala PR, Wetzels JFM, Masereeuw R (2017) Disposition and clinical implications of protein-bound uremic toxins. Clin Sci (Lond) 131:1631\u20131647. https:\/\/doi.org\/10.1042\/CS20160191","journal-title":"Clin Sci (Lond)"},{"key":"4304_CR96","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijpharm.2012.05.079","volume":"452","author":"RN Hines","year":"2013","unstructured":"Hines RN (2013) Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int J Pharm 452:3\u20137. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.05.079","journal-title":"Int J Pharm"},{"key":"4304_CR97","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1432-1033.1997.00625.x","volume":"247","author":"D Lacroix","year":"1997","unstructured":"Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T (1997) Expression of CYP3A in the human liver--evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem 247:625\u2013634","journal-title":"Eur J Biochem"},{"key":"4304_CR98","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/dmd.118.084301","volume":"47","author":"J Badee","year":"2019","unstructured":"Badee J, Qiu N, Parrott N, Collier AC, Schmidt S, Fowler S (2019) Optimization of experimental conditions of automated glucuronidation assays in human liver microsomes using a cocktail approach and ultra-high performance liquid chromatography-tandem mass spectrometry. Drug Metab Dispos 47:124\u2013134. https:\/\/doi.org\/10.1124\/dmd.118.084301","journal-title":"Drug Metab Dispos"},{"key":"4304_CR99","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1056\/NEJM196004212621601","volume":"262","author":"CF Weiss","year":"1960","unstructured":"Weiss CF, Glazko AJ, Weston JK (1960) Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. N Engl J Med 262:787\u2013794. https:\/\/doi.org\/10.1056\/NEJM196004212621601","journal-title":"N Engl J Med"},{"key":"4304_CR100","first-page":"761","volume":"97","author":"JM Sutherland","year":"1959","unstructured":"Sutherland JM (1959) Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J Dis Child 97:761\u2013767","journal-title":"AMA J Dis Child"},{"key":"4304_CR101","first-page":"1","volume":"25","author":"BL Coffman","year":"1997","unstructured":"Coffman BL, Rios GR, King CD, Tephly TR (1997) Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos 25:1\u20134","journal-title":"Drug Metab Dispos"},{"key":"4304_CR102","first-page":"972","volume":"146","author":"TI McRorie","year":"1992","unstructured":"McRorie TI, Lynn AM, Nespeca MK, Opheim KE, Slattery JT (1992) The maturation of morphine clearance and metabolism. Am J Dis Child 146:972\u2013976","journal-title":"Am J Dis Child"},{"key":"4304_CR103","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.pharmthera.2008.02.005","volume":"118","author":"RN Hines","year":"2008","unstructured":"Hines RN (2008) The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol Ther 118:250\u2013267. https:\/\/doi.org\/10.1016\/j.pharmthera.2008.02.005","journal-title":"Pharmacol Ther"},{"key":"4304_CR104","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1517\/17425255.2011.577739","volume":"7","author":"SN de Wildt","year":"2011","unstructured":"de Wildt SN (2011) Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol 7:935\u2013948. https:\/\/doi.org\/10.1517\/17425255.2011.577739","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4304_CR105","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/clpt.2008.59","volume":"83","author":"TD Nolin","year":"2008","unstructured":"Nolin TD, Naud J, Leblond FA, Pichette V (2008) Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 83:898\u2013903. https:\/\/doi.org\/10.1038\/clpt.2008.59","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR106","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1681\/ASN.V122326","volume":"12","author":"F Leblond","year":"2001","unstructured":"Leblond F, Guevin C, Demers C, Pellerin I, Gascon-Barre M, Pichette V (2001) Downregulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12:326\u2013332","journal-title":"J Am Soc Nephrol"},{"key":"4304_CR107","first-page":"1317","volume":"28","author":"FA Leblond","year":"2000","unstructured":"Leblond FA, Giroux L, Villeneuve JP, Pichette V (2000) Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 28:1317\u20131320","journal-title":"Drug Metab Dispos"},{"key":"4304_CR108","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1681\/ASN.2007090974","volume":"19","author":"E Simard","year":"2008","unstructured":"Simard E, Naud J, Michaud J, Leblond FA, Bonnardeaux A, Guillemette C, Sim E, Pichette V (2008) Downregulation of hepatic acetylation of drugs in chronic renal failure. J Am Soc Nephrol 19:1352\u20131359. https:\/\/doi.org\/10.1681\/ASN.2007090974","journal-title":"J Am Soc Nephrol"},{"key":"4304_CR109","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1111\/j.1365-2125.2007.02866.x","volume":"64","author":"M Turpeinen","year":"2007","unstructured":"Turpeinen M, Koivuviita N, Tolonen A, Reponen P, Lundgren S, Miettunen J, Metsarinne K, Rane A, Pelkonen O, Laine K (2007) Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol 64:165\u2013173. https:\/\/doi.org\/10.1111\/j.1365-2125.2007.02866.x","journal-title":"Br J Clin Pharmacol"},{"key":"4304_CR110","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1002\/cpt.1205","volume":"105","author":"ML Tan","year":"2019","unstructured":"Tan ML, Zhao P, Zhang L, Ho YF, Varma MVS, Neuhoff S, Nolin TD, Galetin A, Huang SM (2019) Use of physiologically based pharmacokinetic modeling to evaluate the effect of chronic kidney disease on the disposition of hepatic CYP2C8 and OATP1B drug substrates. Clin Pharmacol Ther 105:719\u2013729. https:\/\/doi.org\/10.1002\/cpt.1205","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR111","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/cpt.807","volume":"103","author":"ML Tan","year":"2018","unstructured":"Tan ML, Yoshida K, Zhao P, Zhang L, Nolin TD, Piquette-Miller M, Galetin A, Huang SM (2018) Effect of chronic kidney disease on nonrenal elimination pathways: a systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin Pharmacol Ther 103:854\u2013867. https:\/\/doi.org\/10.1002\/cpt.807","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR112","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/clpt.1993.127","volume":"54","author":"R Osborne","year":"1993","unstructured":"Osborne R, Joel S, Grebenik K, Trew D, Slevin M (1993) The pharmacokinetics of morphine and morphine glucuronides in kidney failure. Clin Pharmacol Ther 54:158\u2013167","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR113","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/cpt.176","volume":"98","author":"KL Brouwer","year":"2015","unstructured":"Brouwer KL, Aleksunes LM, Brandys B, Giacoia GP, Knipp G, Lukacova V, Meibohm B, Nigam SK, Rieder M, de Wildt SN, Pediatric Transporter Working Group (2015) Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group. Clin Pharmacol Ther 98:266\u2013287. https:\/\/doi.org\/10.1002\/cpt.176","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR114","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1124\/dmd.107.018192","volume":"36","author":"J Naud","year":"2008","unstructured":"Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, Pichette V (2008) Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos 36:124\u2013128. https:\/\/doi.org\/10.1124\/dmd.107.018192","journal-title":"Drug Metab Dispos"},{"key":"4304_CR115","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2165\/00003088-197904030-00002","volume":"4","author":"JC Pechere","year":"1979","unstructured":"Pechere JC, Dugal R (1979) Clinical pharmacokinetics of aminoglycoside antibiotics. Clin Pharmacokinet 4:170\u2013199. https:\/\/doi.org\/10.2165\/00003088-197904030-00002","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR116","doi-asserted-by":"publisher","first-page":"297","DOI":"10.2165\/00003088-197601040-00004","volume":"1","author":"M Barza","year":"1976","unstructured":"Barza M, Weinstein L (1976) Pharmacokinetics of the penicillins in man. Clin Pharmacokinet 1:297\u2013308. https:\/\/doi.org\/10.2165\/00003088-197601040-00004","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR117","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0002-9343(60)90225-4","volume":"28","author":"NS Bricker","year":"1960","unstructured":"Bricker NS, Morrin PA, Kime SW Jr (1960) The pathologic physiology of chronic Bright\u2019s disease. An exposition of the \u201cintact nephron hypothesis\u201d. Am J Med 28:77\u201398","journal-title":"Am J Med"},{"key":"4304_CR118","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/cts.12481","volume":"10","author":"A Chapron","year":"2017","unstructured":"Chapron A, Shen DD, Kestenbaum BR, Robinson-Cohen C, Himmelfarb J, Yeung CK (2017) Does secretory clearance follow glomerular filtration rate in chronic kidney diseases? Reconsidering the intact nephron hypothesis. Clin Transl Sci 10:395\u2013403. https:\/\/doi.org\/10.1111\/cts.12481","journal-title":"Clin Transl Sci"},{"key":"4304_CR119","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1542\/peds.113.S3.1084","volume":"113","author":"MJ Solhaug","year":"2004","unstructured":"Solhaug MJ, Bolger PM, Jose PA (2004) The developing kidney and environmental toxins. Pediatrics 113:1084\u20131091","journal-title":"Pediatrics"},{"key":"4304_CR120","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/MOP.0000000000000318","volume":"28","author":"G Filler","year":"2016","unstructured":"Filler G, Guerrero-Kanan R, Alvarez-Elias AC (2016) Assessment of glomerular filtration rate in the neonate: is creatinine the best tool? Curr Opin Pediatr 28:173\u2013179. https:\/\/doi.org\/10.1097\/MOP.0000000000000318","journal-title":"Curr Opin Pediatr"},{"key":"4304_CR121","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0022-3476(78)80133-4","volume":"92","author":"BS Arant Jr","year":"1978","unstructured":"Arant BS Jr (1978) Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr 92:705\u2013712","journal-title":"J Pediatr"},{"key":"4304_CR122","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1172\/JCI102149","volume":"28","author":"MI Rubin","year":"1949","unstructured":"Rubin MI, Bruck E, Rapoport M, Snively M, McKay H, Baumler A (1949) Maturation of renal function in childhood: clearance studies. J Clin Invest 28:1144\u20131162. https:\/\/doi.org\/10.1172\/JCI102149","journal-title":"J Clin Invest"},{"key":"4304_CR123","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1208\/ps020103","volume":"2","author":"WL Hayton","year":"2000","unstructured":"Hayton WL (2000) Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci 2:E3","journal-title":"AAPS PharmSci"},{"key":"4304_CR124","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s00467-005-2105-4","volume":"21","author":"N Chen","year":"2006","unstructured":"Chen N, Aleksa K, Woodland C, Rieder M, Koren G (2006) Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 21:160\u2013168. https:\/\/doi.org\/10.1007\/s00467-005-2105-4","journal-title":"Pediatr Nephrol"},{"key":"4304_CR125","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1136\/bmj.4.5674.11","volume":"4","author":"KE Kim","year":"1969","unstructured":"Kim KE, Onesti G, Ramirez O, Brest AN, Swartz C (1969) Creatinine clearance in renal disease. A reappraisal. Br Med J 4:11\u201314","journal-title":"Br Med J"},{"key":"4304_CR126","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1093\/clinchem\/38.10.1933","volume":"38","author":"RD Perrone","year":"1992","unstructured":"Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933\u20131953","journal-title":"Clin Chem"},{"key":"4304_CR127","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1365-2125.1981.tb01848.x","volume":"12","author":"JP Kampmann","year":"1981","unstructured":"Kampmann JP, Hansen JM (1981) Glomerular filtration rate and creatinine clearance. Br J Clin Pharmacol 12:7\u201314","journal-title":"Br J Clin Pharmacol"},{"key":"4304_CR128","first-page":"1D","volume":"21","author":"DS Young","year":"1975","unstructured":"Young DS, Pestaner LC, Gibberman V (1975) Effects of drugs on clinical laboratory tests. Clin Chem 21:1D\u2013432D","journal-title":"Clin Chem"},{"key":"4304_CR129","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0022-5347(17)67149-0","volume":"114","author":"F Berglund","year":"1975","unstructured":"Berglund F, Killander J, Pompeius R (1975) Effect of trimethoprim-sulfamethoxazole on the renal excretion of creatinine in man. J Urol 114:802\u2013808","journal-title":"J Urol"},{"key":"4304_CR130","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-198106050-00001","volume":"6","author":"RK Verbeeck","year":"1981","unstructured":"Verbeeck RK, Branch RA, Wilkinson GR (1981) Drug metabolites in renal failure: pharmacokinetic and clinical implications. Clin Pharmacokinet 6:329\u2013345","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR131","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2165\/00003088-197601060-00003","volume":"1","author":"DE Drayer","year":"1976","unstructured":"Drayer DE (1976) Pharmacologically active drug metabolites: therapeutic and toxic activities, plasma and urine data in man, accumulation in renal failure. Clin Pharmacokinet 1:426\u2013443","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR132","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2165\/00003088-199631060-00002","volume":"31","author":"G Davies","year":"1996","unstructured":"Davies G, Kingswood C, Street M (1996) Pharmacokinetics of opioids in renal dysfunction. Clin Pharmacokinet 31:410\u2013422. https:\/\/doi.org\/10.2165\/00003088-199631060-00002","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR133","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/bmj.293.6554.1101","volume":"293","author":"R Osborne","year":"1986","unstructured":"Osborne R, Joel S, Slevin M (1986) Morphine intoxication in renal failure; the role of morphine-6-glucuronide. Br Med J (Clin Res Ed) 293:1101","journal-title":"Br Med J (Clin Res Ed)"},{"key":"4304_CR134","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/clpt.2009.135","volume":"86","author":"DC Brater","year":"2009","unstructured":"Brater DC (2009) Drug dosing in patients with impaired renal function. Clin Pharmacol Ther 86:483\u2013489. https:\/\/doi.org\/10.1038\/clpt.2009.135","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR135","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40262-017-0506-8","volume":"56","author":"A Ivanyuk","year":"2017","unstructured":"Ivanyuk A, Livio F, Biollaz J, Buclin T (2017) Renal drug transporters and drug interactions. Clin Pharmacokinet 56:825\u2013892. https:\/\/doi.org\/10.1007\/s40262-017-0506-8","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR136","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50:81\u201398. https:\/\/doi.org\/10.2165\/11534750-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR137","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/j.1552-4604.1975.tb02362.x","volume":"15","author":"MS Chow","year":"1975","unstructured":"Chow MS, Ronfeld RA (1975) Pharmacokinetic data and drug monitoring: I. Antibiotics and antiarrhythmics. J Clin Pharmacol 15:405\u2013418","journal-title":"J Clin Pharmacol"},{"key":"4304_CR138","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1172\/JCI104848","volume":"42","author":"PL Calcagno","year":"1963","unstructured":"Calcagno PL, Rubin MI (1963) Renal extraction of para-aminohippurate in infants and children. J Clin Invest 42:1632\u20131639. https:\/\/doi.org\/10.1172\/JCI104848","journal-title":"J Clin Invest"},{"key":"4304_CR139","doi-asserted-by":"publisher","first-page":"F197","DOI":"10.1152\/ajprenal.2001.281.2.F197","volume":"281","author":"DH Sweet","year":"2001","unstructured":"Sweet DH, Bush KT, Nigam SK (2001) The organic anion transporter family: from physiology to ontogeny and the clinic. Am J Physiol Ren Physiol 281:F197\u2013F205. https:\/\/doi.org\/10.1152\/ajprenal.2001.281.2.F197","journal-title":"Am J Physiol Ren Physiol"},{"key":"4304_CR140","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1172\/JCI102149","volume":"28","author":"MI Rubin","year":"1949","unstructured":"Rubin MI, Bruck E, Rapoport M (1949) Maturation of renal function in childhood; clearance studies. J Clin Invest 28:1144\u20131162","journal-title":"J Clin Invest"},{"key":"4304_CR141","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2215\/CJN.10350818","volume":"14","author":"JD Momper","year":"2019","unstructured":"Momper JD, Yang J, Gockenbach M, Vaida F, Nigam SK (2019) Dynamic of organic anion transporter-mediated tubular secretion during postnatal human kidney development and maturation. Clin J Am Soc Nephrol 14:540\u2013548. https:\/\/doi.org\/10.2215\/CJN.10350818","journal-title":"Clin J Am Soc Nephrol"},{"key":"4304_CR142","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1203\/01.pdr.0000188697.99079.27","volume":"58","author":"N Pinto","year":"2005","unstructured":"Pinto N, Halachmi N, Verjee Z, Woodland C, Klein J, Koren G (2005) Ontogeny of renal P-glycoprotein expression in mice: correlation with digoxin renal clearance. Pediatr Res 58:1284\u20131289. https:\/\/doi.org\/10.1203\/01.pdr.0000188697.99079.27","journal-title":"Pediatr Res"},{"key":"4304_CR143","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/jps.23433","volume":"102","author":"H Komazawa","year":"2013","unstructured":"Komazawa H, Yamaguchi H, Hidaka K, Ogura J, Kobayashi M, Iseki K (2013) Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure. J Pharm Sci 102:1086\u20131094. https:\/\/doi.org\/10.1002\/jps.23433","journal-title":"J Pharm Sci"},{"key":"4304_CR144","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1124\/dmd.111.039115","volume":"39","author":"J Naud","year":"2011","unstructured":"Naud J, Michaud J, Beauchemin S, Hebert MJ, Roger M, Lefrancois S, Leblond FA, Pichette V (2011) Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos 39:1363\u20131369. https:\/\/doi.org\/10.1124\/dmd.111.039115","journal-title":"Drug Metab Dispos"},{"key":"4304_CR145","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00228-014-1733-7","volume":"70","author":"TL Putt","year":"2014","unstructured":"Putt TL, Duffull SB, Schollum JB, Walker RJ (2014) GFR may not accurately predict aspects of proximal tubule drug handling. Eur J Clin Pharmacol 70:1221\u20131226. https:\/\/doi.org\/10.1007\/s00228-014-1733-7","journal-title":"Eur J Clin Pharmacol"},{"key":"4304_CR146","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/clpt.1983.251","volume":"34","author":"R Hori","year":"1983","unstructured":"Hori R, Okumura K, Kamiya A, Nihira H, Nakano H (1983) Ampicillin and cephalexin in renal insufficiency. Clin Pharmacol Ther 34:792\u2013798","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR147","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1021\/acs.molpharmaceut.6b00332","volume":"13","author":"CH Hsueh","year":"2016","unstructured":"Hsueh CH, Yoshida K, Zhao P, Meyer TW, Zhang L, Huang SM, Giacomini KM (2016) Identification and quantitative assessment of uremic solutes as inhibitors of renal organic anion transporters, OAT1 and OAT3. Mol Pharm 13:3130\u20133140. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b00332","journal-title":"Mol Pharm"},{"key":"4304_CR148","doi-asserted-by":"publisher","first-page":"38","DOI":"10.2165\/00003088-198916010-00003","volume":"16","author":"CA van Ginneken","year":"1989","unstructured":"van Ginneken CA, Russel FG (1989) Saturable pharmacokinetics in the renal excretion of drugs. Clin Pharmacokinet 16:38\u201354. https:\/\/doi.org\/10.2165\/00003088-198916010-00003","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR149","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/ki.1980.181","volume":"18","author":"MW Anders","year":"1980","unstructured":"Anders MW (1980) Metabolism of drugs by the kidney. Kidney Int 18:636\u2013647","journal-title":"Kidney Int"},{"key":"4304_CR150","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/0006-2952(66)90220-6","volume":"15","author":"RA Deitrich","year":"1966","unstructured":"Deitrich RA (1966) Tissue and subcellular distribution of mammalian aldehyde-oxydizing capacity. Biochem Pharmacol 15:1911\u20131922","journal-title":"Biochem Pharmacol"},{"key":"4304_CR151","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0024-3205(00)00915-2","volume":"68","author":"C Woodland","year":"2000","unstructured":"Woodland C, Ito S, Granvil CP, Wainer IW, Klein J, Koren G (2000) Evidence of renal metabolism of ifosfamide to nephrotoxic metabolites. Life Sci 68:109\u2013117","journal-title":"Life Sci"},{"key":"4304_CR152","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.lab.2004.09.002","volume":"144","author":"K Aleksa","year":"2004","unstructured":"Aleksa K, Halachmi N, Ito S, Koren G (2004) Renal ontogeny of ifosfamide nephrotoxicity. J Lab Clin Med 144:285\u2013293. https:\/\/doi.org\/10.1016\/j.lab.2004.09.002","journal-title":"J Lab Clin Med"},{"key":"4304_CR153","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1177\/009127009903900504","volume":"39","author":"R Loebstein","year":"1999","unstructured":"Loebstein R, Atanackovic G, Bishai R, Wolpin J, Khattak S, Hashemi G, Gobrial M, Baruchel S, Ito S, Koren G (1999) Risk factors for long-term outcome of ifosfamide-induced nephrotoxicity in children. J Clin Pharmacol 39:454\u2013461","journal-title":"J Clin Pharmacol"},{"key":"4304_CR154","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1146\/annurev.bi.45.070176.003215","volume":"45","author":"HF DeLuca","year":"1976","unstructured":"DeLuca HF, Schnoes HK (1976) Metabolism and mechanism of action of vitamin D. Annu Rev Biochem 45:631\u2013666. https:\/\/doi.org\/10.1146\/annurev.bi.45.070176.003215","journal-title":"Annu Rev Biochem"},{"key":"4304_CR155","doi-asserted-by":"publisher","first-page":"126","DOI":"10.2165\/00003088-197601020-00004","volume":"1","author":"L Dettli","year":"1976","unstructured":"Dettli L (1976) Drug dosage in renal disease. Clin Pharmacokinet 1:126\u2013134","journal-title":"Clin Pharmacokinet"},{"key":"4304_CR156","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0025-7125(16)32094-6","volume":"58","author":"L Dettli","year":"1974","unstructured":"Dettli L (1974) Individualization of drug dosage in patients with renal disease. Med Clin North Am 58:977\u2013985","journal-title":"Med Clin North Am"},{"key":"4304_CR157","unstructured":"Study on off-label use of medicinal products in the European Union, NIVEL report, 2017. Available at https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/documents\/2017_02_28_final_study_report_on_off-label_use_.pdf . Accessed 13 May 2019"},{"key":"4304_CR158","unstructured":"www.kinderformularium.nl . Accessed 25 June 2019"},{"key":"4304_CR159","unstructured":"Drug prescribing in renal failure. Available at http:\/\/www.kdp-baptist.louisville.edu\/renalbook\/ . Accessed 25 June 2019"},{"issue":"7","key":"4304_CR160","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.2215\/CJN.08140718","volume":"14","author":"Rachel F. Eyler","year":"2019","unstructured":"Eyler RF, Shvets K (2019) Clinical pharmacology of antibiotics. Clin J Am Soc Nephrol. Clin J Am Soc Nephrol 14(7):1080\u20131090. https:\/\/doi.org\/10.2215\/CJN.08140718","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"4304_CR161","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1046\/j.1523-1755.2000.00943.x","volume":"57","author":"IA MacPhee","year":"2000","unstructured":"MacPhee IA, Spreafico S, Bewick M, Davis C, Eastwood JB, Johnston A, Lee T, Holt DW (2000) Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. Kidney Int 57:1164\u20131168. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00943.x","journal-title":"Kidney Int"},{"key":"4304_CR162","first-page":"25","volume":"262","author":"B Frances","year":"1992","unstructured":"Frances B, Gout R, Monsarrat B, Cros J, Zajac JM (1992) Further evidence that morphine-6 beta-glucuronide is a more potent opioid agonist than morphine. J Pharmacol Exp Ther 262:25\u201331","journal-title":"J Pharmacol Exp Ther"},{"key":"4304_CR163","unstructured":"FDA pharmacokinetics in patients with impaired renal function \u2014 study design, data analysis, and impact on dosing and labeling 2010. Available at: https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm204959.pdf . Accessed on March 11, 2019"},{"key":"4304_CR164","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 (2013) clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1\u2013150"},{"key":"4304_CR165","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1086\/652287","volume":"50","author":"MF Schreuder","year":"2010","unstructured":"Schreuder MF, van der Flier M, Knops NB, Koster-Kamphuis L, Bruggemann RJ (2010) Oseltamivir dosing in children undergoing hemodialysis. Clin Infect Dis 50:1427\u20131428. https:\/\/doi.org\/10.1086\/652287","journal-title":"Clin Infect Dis"},{"key":"4304_CR166","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/clpt.2012.64","volume":"92","author":"JS Barrett","year":"2012","unstructured":"Barrett JS, Della Casa Alberighi O, Laer S, Meibohm B (2012) Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther 92:40\u201349. https:\/\/doi.org\/10.1038\/clpt.2012.64","journal-title":"Clin Pharmacol Ther"},{"key":"4304_CR167","volume-title":"Directory of Drug Dosage in Kidney Disease","author":"G Seyffart","year":"2011","unstructured":"Seyffart G (2011) Directory of Drug Dosage in Kidney Disease. Dustri-Verlag, Munich-Orlando"},{"key":"4304_CR168","volume-title":"The renal drug handbook","author":"C Ashley","year":"2009","unstructured":"Ashley C, Currie A (2009) The renal drug handbook. Radcliffe, Oxford"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04304-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-019-04304-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-019-04304-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T20:04:57Z","timestamp":1695067497000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-019-04304-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,2]]},"references-count":168,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4304"],"URL":"https:\/\/doi.org\/10.1007\/s00467-019-04304-9","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,2]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}